MicroPort Scientific Corporation announced unaudited financial results for its affiliate, Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("Endovastec"), for the nine months ended 30 September 2025. MicroPort holds a 40.32% stake in Endovastec. Endovastec reported revenue of RMB 1,014.78 million, up 4.66% year-on-year, and net profit attributable to equity owners of RMB 429.06 million, down 22.46% from the prior year.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MicroPort Scientific Corporation published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.